Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Compositions containing piperacillin and tazobactam useful for injection

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • Publication Date:
    April 20, 2006
  • معلومة اضافية
    • Document Number:
      20060084639
    • Appl. No:
      11/250716
    • Application Filed:
      October 14, 2005
    • نبذة مختصرة :
      The invention provides a pharmaceutical composition comprising piperacillin, tazobactam, an aminocarboxylic acid, and a buffer in a sodium lactate diluent. The invention further relates to a method of treating a bacterial infection and an LR condition in a human which comprises administering to said human an effective amount of a pharmaceutical composition comprising piperacillin, tazobactam, an aminocarboxylic acid, and a buffer in a sodium lactate diluent.
    • Inventors:
      Cohen, Jonathan Marc (Monroe, NY, US); Shah, Syed M. (East Hanover, NJ, US); Fawzi, Mahdi (Morristown, NJ, US)
    • Assignees:
      Wyeth (Madison, NJ, US)
    • Claim:
      1. A pharmaceutical composition which comprises piperacillin, tazobactam, an aminocarboxylic acid and a buffer in a sodium lactate diluent.
    • Claim:
      2. The pharmaceutical compositon according to claim 1, wherein the sodium lactate diluent is lactated Ringer's solution.
    • Claim:
      3. The pharmaceutical composition according to claim 1, wherein the sodium lactate diluent is Hartmann's solution.
    • Claim:
      4. The pharmaceutical composition according to claim 1 wherein the buffer is citric acid or a salt thereof.
    • Claim:
      5. The pharmaceutical composition according to claim 4, wherein the buffer is sodium citrate.
    • Claim:
      6. The pharmaceutical composition according to claim 4 in which the citrate is in the range of about 0.25 mg/ml to about 25 mg/ml.
    • Claim:
      7. The pharmaceutical composition according to claim 6 in which the citrate is in the range of about 0.6 mg/ml to about 15 mg/ml.
    • Claim:
      8. The pharmaceutical composition according to claim 1 wherein the pH is about 6.5.
    • Claim:
      9. The pharmaceutical composition according to claim 1, wherein the aminocarboxylic acid is EDTA or a salt thereof.
    • Claim:
      10. The pharmaceutical composition according to claim 9, wherein the salt of EDTA is selected from calcium disodium salt, dicalcium salt, diammonium salt, dipotassium salt, disodium salt, tetrasodium salt, tripotassium salt, and trisodium salt.
    • Claim:
      11. The pharmaceutical composition according to claim 1, wherein the aminocarboxylic acid is selected from diethylenetriaminepentaacetic acid (DTPA), hydroxyethylenediaminetriacetic acid (HEDTA), nitrilotriacetic acid (NTA), O,O′-bis(2-aminoethyl)ethyleneglycol-N,N,N′,N′-tetraacetic acid (EGTA), and trans-1,2-diaminocyclohexane-N,N,N′,N′-tetraacetic acid (CyDTA) or a pharmaceutically acceptable salt thereof.
    • Claim:
      12. The pharmaceutical composition according to claim 1, in which the aminocarboxylic acid is present in the range of about 0.002 mg/ml to about 10 mg/ml.
    • Claim:
      13. The pharmaceutical composition according to claims 12, in wihich the aminocarboxylic acid is present in the range of about 0.003 to about 1 mg/ml.
    • Claim:
      14. The pharmaceutical composition according to claim 1, wherein the piperacillin is present in the range of about 8 mg/ml to about 500 mg/ml.
    • Claim:
      15. The pharmaceutical composition according to claims 14, wherein the piperacillin is present in the range of about 12 mg/ml to about 300 mg/ml.
    • Claim:
      16. The pharmaceutical composition according to claim 1, wherein the tazobactam is present in the range of about 0.1 mg/ml to about 125 mg/ml.
    • Claim:
      17. The pharmaceutical composition according to claim 16, wherein the tazobactam is present in the range of about 1.5 mg/ml to about 75 mg/ml.
    • Claim:
      18. The pharmaceutical composition according to claim 1, which further comprises an aminoglycoside.
    • Claim:
      19. The pharmaceutical composition according to claim 18, wherein the aminoglycoside is amikacin.
    • Claim:
      20. The pharmaceutical composition according to claim 18, wherein the aminoglycoside is tobramycin.
    • Claim:
      21. The pharmaceutical composition according to claim 18, in which the aminoglycoside is present in the range of about 0.1 mg/ml to about 75 mg/ml.
    • Claim:
      22. A method of treating a bacterial infection and an LR condition in a human which comprises administering to said human an effective amount of a pharmaceutical composition according to claim 1.
    • Claim:
      23. A method of treating a bacterial infection and an LR condition in a human which comprises administering to said human an effective amount of a pharmaceutical composition according to claim 18.
    • Current U.S. Class:
      514192/000
    • Current International Class:
      61; 61; 61
    • الرقم المعرف:
      edspap.20060084639